Candel Therapeutics, Inc. (CADL)
10.18
+0.02
(+0.20%)
USD |
NASDAQ |
Oct 02, 16:00
10.20
+0.02
(+0.15%)
After-Hours: 20:00
Candel Therapeutics Enterprise Value : 622.84M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 622.84M |
| October 01, 2026 | 621.31M |
| September 30, 2026 | 642.63M |
| September 29, 2026 | 676.12M |
| September 28, 2026 | 699.72M |
| September 25, 2026 | 686.78M |
| September 24, 2026 | 727.12M |
| September 23, 2026 | 707.33M |
| September 22, 2026 | 749.95M |
| September 21, 2026 | 701.24M |
| September 18, 2026 | 673.84M |
| September 17, 2026 | 711.13M |
| September 16, 2026 | 686.78M |
| September 15, 2026 | 694.39M |
| September 14, 2026 | 660.51M |
| September 11, 2026 | 650.62M |
| September 10, 2026 | 710.37M |
| September 09, 2026 | 774.31M |
| September 08, 2026 | 807.04M |
| September 04, 2026 | 820.74M |
| September 03, 2026 | 835.21M |
| September 02, 2026 | 852.71M |
| September 01, 2026 | 826.07M |
| August 31, 2026 | 842.82M |
| August 28, 2026 | 842.82M |
| Date | Value |
|---|---|
| August 27, 2026 | 894.58M |
| August 26, 2026 | 858.80M |
| August 25, 2026 | 883.16M |
| August 24, 2026 | 826.83M |
| August 21, 2026 | 847.39M |
| August 20, 2026 | 788.01M |
| August 19, 2026 | 875.55M |
| August 18, 2026 | 765.18M |
| August 17, 2026 | 773.55M |
| August 14, 2026 | 740.06M |
| August 13, 2026 | 746.15M |
| August 12, 2026 | 660.90M |
| August 11, 2026 | 658.61M |
| August 10, 2026 | 647.19M |
| August 07, 2026 | 654.04M |
| August 06, 2026 | 653.28M |
| August 05, 2026 | 644.15M |
| August 04, 2026 | 647.96M |
| August 03, 2026 | 614.46M |
| July 31, 2026 | 609.90M |
| July 30, 2026 | 599.24M |
| July 29, 2026 | 563.46M |
| July 28, 2026 | 584.78M |
| July 27, 2026 | 606.09M |
| July 24, 2026 | 575.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arcturus Therapeutics Holdings, Inc. | 201.80M |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.90M |
| Total Expenses (Quarterly) | 38.90M |
| EPS Diluted (Quarterly) | -0.5248 |
| Earnings Yield | -13.85% |
| Normalized Earnings Yield | -12.00 |